Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 1, 2010, Pages 314-319

  Kimberlina, Christopher R ^a   Bornholdta, Zachary A ^a   Lib, Sheng ^b   Woods Jr , Virgil L ^b   MacRae, Ian J ^a   Saphire, Erica Ollmann ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

dsRNA; Interferon; Structure; Virus

Indexed keywords

DICER; DOUBLE STRANDED RNA; MONOMER; PROTEIN; PROTEIN MDA 5 PROTEIN; PROTEIN VP35; RETINOIC ACID INDUCIBLE PROTEIN I; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CRYSTAL STRUCTURE; EBOLA VIRUS; GENE SILENCING; INNATE IMMUNITY; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRUS ATTACHMENT; VIRUS INFECTION;

HUMANS; IMMUNITY, INNATE; MACROMOLECULAR SUBSTANCES; MASS SPECTROMETRY; MODELS, MOLECULAR; NUCLEIC ACID CONFORMATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; RNA, DOUBLE-STRANDED; SCATTERING, SMALL ANGLE; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EBOLA VIRUS; RESTON EBOLAVIRUS;

EID: 76249120477     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0910547107     Document Type: Article

References (55)

1. Sanchez A, Geisbert TW, Feldmann H (2007) Filoviridae: Marburg and Ebola Viruses. In Fields Virology, eds Knipe DM, Howley PM (Lippincott Williams & Wilkins, Philidelphia), pp 1409-1448.
2. Towner JS, et al. (2008) Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 4:e1000212.
3. Bwaka MA, et al. (1999) Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: Clinical observations in 103 patients. J Infect Dis 179 (Suppl 1):S1-S7.
4. Barrette RW, et al. (2009) Discovery of swine as a host for the Reston ebolavirus. Science 325:204-206.
5. CDC (1990) Update: Filovirus infections among persons with occupational exposure to nonhuman primates. MMWR Morb Mortal Wkly 39:266-7; 273.
6. Editorial Team (2009) Ebola Reston virus detected pigs in the Philippines. Euro Surveill 14: pii=19105.
7. Towner JS, et al. (2004) Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 78:4330-4341.
8. Baize S, et al. (1999) Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 5:423-426.
9. Sanchez A, et al. (2004) Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: Cellular responses, virus load, and nitric oxide levels. J Virol 78:10370-10377.
10. Yoneyama M, et al. (2004) The RNA helicase RIG-I has an essential function in doublestranded RNA-induced innate antiviral responses. Nat Immunol 5:730-737.
11. Andrejeva J, et al. (2004) The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci USA 101:17264-17269.
12. Schmidt A, et al. (2009) 5′-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proc Natl Acad Sci USA 106:12067-12072.
13. Schlee M, et al. (2009) Recognition of 5′ triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 31:25-34.
14. Li X, et al. (2009) Structural basis of double-stranded RNA recognition by the RIG-I like receptor MDA5. Arch Biochem Biophys 488:23-33.
15. Li X, et al. (2009) The RIG-I-like receptor LGP2 recognizes the termini of double-stranded RNA. J Biol Chem 284:13881-13891.
16. Crary SM, Towner JS, Honig JE, Shoemaker TR, Nichol ST (2003) Analysis of the role of predicted RNA secondary structures in Ebola virus replication. Virology 306: 210-218.
17. Volchkov VE, et al. (1999) Characterization of the L gene and 5′ trailer region of Ebola virus. J Gen Virol 80:355-362.
18. Spiropoulou CF, et al. (2009) RIG-I activation inhibits ebolavirus replication. Virology 392:11-15.
19. Harcourt BH, Sanchez A, Offermann MK (1998) Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells. Virology 252:179-188.
20. Harcourt BH, Sanchez A, Offermann MK (1999) Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells. J Virol 73: 3491-3496.
21. Basler CF, et al. (2003) The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 77:7945-7956.
22. Basler CF, et al. (2000) The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci USA 97:12289-12294.
23. Feng Z, Cerveny M, Yan Z, He B (2007) The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J Virol 81:182-192.
24. Schümann M, Gantke T, Mühlberger E (2009) Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J Virol 83:8993-8997.
25. Haasnoot J, et al. (2007) The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog 3:e86.
26. Cárdenas WB, et al. (2006) Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol 80: 5168-5178.
27. Hartman AL, Towner JS, Nichol ST (2004) A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. Virology 328:177-184.
28. Hartman AL, Ling L, Nichol ST, Hibberd ML (2008) Whole genome expression profiling reveals that inhibition of host innate immune response pathways by ebola virus can be reversed by a single amino acid change in the VP35 protein. J Virol 82:5348-5358.
29. Hartman AL, et al. (2008) Inhibition of IRF-3 activation by VP35 is critical for the high virulence of Ebola virus. J Virol 82:2699-2704.
30. Hartman AL, Dover JE, Towner JS, Nichol ST (2006) Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication. J Virol 80:6430-6440.
31. Leung DW, et al. (2009) Structure of the Ebola VP35 interferon inhibitory domain. Proc Natl Acad Sci USA 106:411-416.
32. Holm L, Kääriäinen S, Rosenström P, Schenkel A (2008) Searching protein structure databases with DaliLite v.3. Bioinformatics 24:2780-2781.
33. Reid SP, Cárdenas WB, Basler CF (2005) Homo-oligomerization facilitates the interferon-antagonist activity of the ebolavirus VP35 protein. Virology 341:179-189.
34. Boehmann Y, Enterlein S, Randolf A, Mühlberger E (2005) A reconstituted replication and transcription system for Ebola virus Reston and comparison with Ebola virus Zaire. Virology 332:406-417.
35. Johnson RF, McCarthy SE, Godlewski PJ, Harty RN (2006) Ebola virus VP35-VP40 interaction is sufficient for packaging 3E-5E minigenome RNA into virus-like particles. J Virol 80:5135-5144.
36. Huang Y, Xu L, Sun Y, Nabel GJ (2002) The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol Cell 10:307-316.
37. Chang TH, et al. (2009) Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog 5:e1000493.
38. Kubota T, et al. (2009) Ebolavirus VP35 interacts with the cytoplasmic dynein light chain 8. J Virol 83:6952-6956.
39. Prins KC, Cárdenas WB, Basler CF (2009) Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J Virol 83:3069-3077.
40. Kash JC, et al. (2006) Global suppression of the host antiviral response by Ebola- and Marburgviruses: Increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol 80:3009-3020.
41. MacRae IJ, Zhou K, Doudna JA (2007) Structural determinants of RNA recognition and cleavage by Dicer. Nat Struct Mol Biol 14:934-940.
42. Lund E, Dahlberg JE (2006) Substrate selectivity of exportin 5 and Dicer in the biogenesis of microRNAs. Cold Spring Harb Symp Quant Biol 71:59-66.
43. Miyoshi K, et al. (2001) Structure of the mouse Stat 3/5 locus: Evolution from Drosophila to zebrafish to mouse. Genomics 71:150-155.
44. Baulcombe DC, Molnár A (2004) Crystal structure of p19 - a universal suppressor of RNA silencing. Trends Biochem Sci 29:279-281.
45. Chao JA, et al. (2005) Dual modes of RNA-silencing suppression by Flock House virus protein B2. Nat Struct Mol Biol 12:952-957.
46. Bornholdt ZA, Prasad BV (2008) X-ray structure of NS1 from a highly pathogenic H5N1 influenza virus. Nature 456:985-988.
47. Cheng A, Wong SM, Yuan YA (2009) Structural basis for dsRNA recognition by NS1 protein of influenza A virus. Cell Res 19:187-195.
48. Vonrhein C, Blanc E, Roversi P, Bricogne G (2007) Automated structure solution with autoSHARP. Methods Mol Biol 364:215-230.
49. Langer G, Cohen SX, Lamzin VS, Perrakis A (2008) Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7. Nat Protoc 3:1171-1179.
50. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-326.
51. Strong M, et al. (2006) Toward the structural genomics of complexes: Crystal structure of a PE/PPE protein complex from Mycobacterium tuberculosis. Proc Natl Acad Sci USA 103:8060-8065.
52. McCoy AJ, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40:658-674.
53. Adams PD, et al. (2002) PHENIX: Building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 58:1948-1954.
54. Painter J, Merritt EA (2006) Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr D Biol Crystallogr 62:439-450.
55. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126-2132.